MedWatch·Industry news·Business & finance·4d agoDemant closes KIND factory in Germany: “The technology was outdated”The closure signals ongoing consolidation and manufacturing modernisation within the global hearing aid industry, with Demant streamlining its KIND integration at the cost of around 200 jobs in Germany.
Audiology Worldnews·Industry news·Hearing aids·5d agoReveal is twice the launch anyone expected from Oticon: a dual AI system hearing aidOticon Reveal's dual-AI architecture signals an industry-wide push toward multi-model AI processing in premium hearing aids, potentially raising patient expectations and competitive pricing pressure across the market.＋Save
MedWatch·Industry news·Business & finance·5d agoDemant expects hefty refund: “Now, the net effect of customs duties is the other way around”A near-full tariff refund for Demant signals that trade policy reversals can meaningfully shift the financial outlook of major audiology manufacturers, which may influence product pricing and investment decisions across the sector.＋Save
Audiology Worldnews·Financial report·Business & finance·5d agoDemant reports 7% organic growth and upgrades 2026 outlookStrong organic growth at a market leader signals continued R&D investment and competitive pricing pressure across the hearing aid industry.＋Save
MedWatch·Industry news·Business & finance·5d agoDemant buys Amplifon’s UK chain: “We decided to make this a major project”This acquisition signals accelerating vertical integration in the UK hearing care market, which could reshape referral pathways, brand competition, and independent clinic economics.＋Save
MedWatch·Industry news·Business & finance·6d agoDemant CEO steps up efforts despite tough competition ahead: “We’re not done yet”Intensifying competition among major hearing-aid manufacturers could accelerate product innovation and affect pricing and supply options available to clinics.＋Save
MedWatch·Industry news·Business & finance·6d agoAnalyst expects tense competition following Demant's improved outlookIntensifying product competition among the Big Three hearing aid manufacturers could accelerate innovation and affect pricing and product availability for clinics and dispensers.＋Save
MedWatch·Financial report·Business & finance·6d agoDemant CEO on upward revision: “There is strong momentum in the business”Demant's upward financial revision signals continued market expansion in the hearing industry, which may influence competitive dynamics, pricing, and product investment across the sector.＋Save
MedWatch·Financial report·Business & finance·6d agoDemant upgrades outlook and launches new product initiativeDemant's upgraded growth forecast signals continued market expansion in hearing healthcare, which could influence competitive pricing, product availability, and clinic partnership strategies.＋Save
Hearing Tracker·Financial report·Business & finance·8d agoDemant Reports Strong Q2 Hearing Aid Growth, Raises 2026 OutlookDemant's upward-revised outlook signals continued market growth in hearing aids, which may reflect broader adoption trends relevant to clinic owners and the competitive landscape.＋Save
MedWatch·Financial report·Business & finance·8d agoDemant upgrade widely expected up to Q2 reportAn earnings upgrade at Demant would signal strong commercial momentum for Oticon's latest product line, which may influence device availability, pricing, and competitive dynamics across audiology clinics.＋Save
MedWatch·Financial report·Business & finance·2w agoPositive outlook at Demant prompts Nordea to raise its price targetDemant's strong financial outlook signals continued investment capacity in hearing aid innovation, which may influence product pipelines and market competition for clinics and dispensers.＋Save
MedWatch·Financial report·Hearing aids·3w agoDemant launch could boost the market for cosmetic hearing aidsIncreased competition in cosmetic and mainstream hearing aid segments from two of the industry's largest manufacturers could broaden patient device choice and influence pricing over time.＋Save
MedWatch·Industry news·Business & finance·3w agoDemant grew market share among US veterans in JuneShifts in the VA hearing aid market signal changing competitive dynamics among major manufacturers, with Amplifon's pending acquisition of GN Hearing poised to reshape the landscape further.＋Save
MedWatch·Financial report·Business & finance·4w agoDistrust of GN' management as Demant surges aheadThe sale of GN Hearing and Demant's rising momentum signal a potential shift in the competitive balance of the global hearing aid industry, which could affect product availability, pricing, and supplier relationships for clinics over the medium term.＋Save
MedWatch·Financial report·Business & finance·5w agoBank of America looks favorably upon Demant's launch of Oticon ZealFavorable analyst coverage of Demant signals that Wall Street views the Oticon Zeal launch as a meaningful commercial catalyst, which may influence the company's R&D investment and competitive positioning in the hearing aid market.＋Save
MedWatch·Industry news·Regulatory & legal·6w agoDemant suspends protection programs after Danish FSA orderRegulatory intervention by a national financial authority on a major hearing aid group's consumer programs signals growing scrutiny of financial practices within the hearing care industry.＋Save
MedWatch·Industry news·Business & finance·6w agoDemant has made IT security a top priority after cyberattack in 2019The 2019 Demant cyberattack was one of the costliest in the medical device sector, and its aftermath highlights the growing cybersecurity risk facing hearing technology supply chains and clinic IT infrastructure.＋Save
MedWatch·Industry news·Business & finance·6w agoMedia: Investors criticize GN board following hearing aid business saleThe exclusion of top-tier bidders from GN's hearing aid sale could reshape ownership and competition in the global hearing aid market, with downstream effects on product availability and pricing for clinics and patients.＋Save
Audiology Worldnews·Industry news·Business & finance·6w agoDemant appoints new lead of Hearing Aids so Nielsen can sharpen CEO focusLeadership restructuring at a top-three global hearing aid manufacturer can signal shifts in strategic direction — such as R&D priorities, market positioning, or partnership focus — that may eventually affect product availability and clinical options.＋Save
MedWatch·Industry news·Business & finance·7w agoDemant on track for best quarter since the turn of the millenniumDemant's record-breaking quarter signals strong market demand for the Oticon Zeal platform, which may influence product availability, competitive pricing, and the broader hearing aid market landscape.＋Save
MedWatch·Financial report·Business & finance·8w agoMorgan Stanley upgrades Demant and Sonova on positive market prospectsA Morgan Stanley upgrade signals that institutional investors expect a hearing aid market recovery, which could translate into increased R&D spending and product innovation from two of the industry's largest manufacturers.＋Save
MedWatch·Industry news·Hearing aids·2mo agoDemant product stands out in new market analysisStrong investor-driven preference data for the Oticon Zeal signals meaningful competitive pressure in the premium hearing aid segment that clinic owners and dispensers should monitor when making stocking decisions.＋Save
MedWatch·Financial report·Business & finance·2mo agoAnalysts see prospects for upward revision at Demant after strong 2026 startA broadly improving hearing aid market signals potentially greater investment in R&D, product innovation, and access initiatives that could shape the audiology landscape over the coming years.＋Save
MedWatch·Industry news·Hearing aids·2mo agoDemant reaps rewards of a popular relaunch among US veteransSecuring a VA supply contract is a significant commercial milestone that shifts market share within the largest single hearing aid dispensing channel in the US.＋Save
Audiology Worldnews·Industry news·Business & finance·2mo agoDemant completes divestment of Oticon MedicalDemant's complete exit from implantable hearing solutions reshapes the competitive landscape for bone-anchored and cochlear implant markets, potentially affecting clinician supplier choices and long-term product continuity.＋Save
MedWatch·Industry news·Regulatory & legal·2mo agoDemant CEO warns about new EU AI regulationsEU AI regulation could slow the development pipeline and market availability of AI-powered hearing devices, with downstream effects on the full audiology supply chain.＋Save
Hearing Tracker·Industry news·Business & finance·3mo agoDemant Names Bassel Rifai President of Hearing AidsLeadership transitions at top-five hearing aid manufacturers can influence product strategy, partnership priorities, and market direction for the broader audiology field.＋Save
MedWatch·Financial report·Business & finance·3mo agoDanske Bank sees promising outlook for Demant after strong Q1Investor confidence in Demant signals continued R&D and commercial momentum for Oticon products, which may shape future device availability and competition in the hearing aid market.＋Save
MedWatch·Financial report·Business & finance·3mo agoDemant delivers strong start to the year on relaunch momentumDemant's relaunch-driven momentum suggests the company is prioritizing portfolio refresh over entirely new platforms, which may affect the pace of clinically meaningful innovation in the near term.＋Save
